Prof. José Luis González Larriba

Complutense University of Madrid, Madrid, Spain

Hospital Clínico San Carlos, Madrid, Spain

Email: jglarriba@salud.madrid.org

Qualifications

2017 Full Professor, Complutense University of Madrid, Madrid, Spain

2005 Head of Thoracic, Urologic Tumors and Melanoma, Hospital Clínico San Carlos, Madrid, Spain

1993 Ph.D., Complutense University of Madrid, Madrid, Spain

1978 M.D., Complutense University of Madrid, Madrid, Spain

Publications (Selected)

1. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. N.Viñolas, R. García-Campelo, M.Majem, E. Carcereny, D. Isla, J.L.González-Larriba, et al. BMC Psicol. 2020;8:123 ; htps://doi.org/10.1186/s40359-020-00489-z
2. First-Line Lorlaitinib or Crizotinib in Advanced ALK-Posiitve Lung Cancer. Referenciado como participante en el estudio. N.Engl.J.Med. 383;21: 2018-2029; 2020
3. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). A. Rodríguez-Vida, A. Bamias, E. Esteban, M.I.Saez, M. López-Brea. D. Castellano, C. Caballero, J.L. González-Larriba, et al. Brit.J.Urol Int. 2020;126: 559-567; doi:10.1111/bju.15165
4. Epidemiology, treatment and survival in small cell lung cancer in Sapin: data from the Thoracic Tumor Registry. F. Franco, E. Carcereny, M. Guirado, A.L.Ortega, R. López-Castro, D. Rodríguez-Abreu, R. García-Campelo, E. Del Barco, O. Juan, F. Aparisi, J.L. González Larriba et al (en prensa)
5. Phase II Clinical Trial with Metronomic oral Vinorelbine and Tri-weekly Cisplatin as Induction Therapy Subsequently Concomitant with Radiotherapy in Patients with Locally Advanced Unresectable, Non-Small Cell Lung Cancer. Analysis of Survival and Value of ctDNA for patient selection. M. Provencio, M.Majem, M.Guirado, B. Massuti, R. de las Peñas, A. Laura Ortega, M. Domine, R. Marse, M.A. Sala, A. Paredes, T. Morán, S. Vazquez, J. Coves, J.L. González Larriba et al. (en prensa)
6. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using the BEAMing technology. P. Garrido, L. Paz-Ares, M.Majem, T.Morán, JM Trigo, J.Bosch-Barrera, R. García-Campelo, J.L. Gonzalez Larriba et al. (en prensa)
7. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. J. Remon, E. Nadal, M.Domine, J.Ruffinelli, Y.García, J.C. Pardo, R. López, A. Cilleruelo, R. García-Campelo, P.Martin, O.Juan, J.L. González Larriba et al. Lung Cancer https://doi.org/10.1016/j.lungcan.2020.06.034
8. Prospective exploratory analysis of angiogenic biomarkers in advanced NSCLC patients treated with bevacizumab plus chemotherapy. The ANGIOMET study. E.Jantus, B. Massuti Sureda, J.L. González Larriba et al. (en prensa)
9. Safety and Patient-Reported Outcomes of Atezolizumab plus Chemotherapy with or Without Bevacizumab versus Bevacizumab plus Chemotherapy in Non-Small Cell Lung Cancer. M. Reck, T Wehler, F. Orlandi, N. Nogami, C. Barone, D. Moro-Sibilot, M. Shtivelband, J.L. González Larriba et al. J. Clin.Oncol. 38.2020. https://doi.org/10.1200/JCO.19.03158
10. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. M. Barquín, V. Calvo, F. García García, B. Nuñez, E. Sanchez-Herrero, R. Serna-Blasco, M. Auglyte, E. Carcereny, D. Rodriguez-Abreu, R. Lopez Castro, M. Guirado, C. Camps, J.Bosch-Barrera, B. Massuti, Ana Laura Ortega, E. Del Barco, J.L. González Larriba et al. Cancer Epidemiology. https://doi.org/10.1016/jcanep.2020.101737
11. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Referenciado como participante en el estudio. N.Engl.J.Med. 2018; 378:113-125; DOI: 10.1056/NEJMoa1713137
12. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Referenciado como participante en el estudio. N.Engl.J.Med 2018; 378:1408-1418. DOI: 10.1056/NEJMoa1715546
13. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. Referenciado como participante en el estudio. N.Eng.J.Med. 2018; 378:2288-2301. DOI: 10.1056/NEJMoa1716948
14. Overall Survival with Osirmetinib in Untreated, EGFR-Mutated Advanced NSCLC. Referenciado como participante en el estudio.N.Engl.J.Med 2020; 382:41-50; doi: 10.1056/NEJMoa1913662. Epub 2019. Nov 21
15. Safety and patient-reported outcomes in a randomized phase III study of atezolizumab plus chemotherapy with or without bevacizumab in first-line nonsquamous NSCLC. M. Reck, T. Wheler, F. Orlandi, N.Nogami, C. Barone, D. Moro-Sibilot, M. Shtivelband, J.L. González Larriba et al. (en prensa)
16. Transcriptomic immune correlates in Head and Neck cancer and Lung Adenocarcinomas. C. Saiz-Ladera, M. Baliu-Piqué, A. Manzano, J.L. González Larriba et al. (en prensa)
17. ASTRIS, A Large Real-World Study to Evaluate the Effect of Osimertinib on Epidermal Growth Fcdtor Receptor T790M Mutation-Posiitve Non-Small Cell Lung Cancer: Spanish Baseline Data and Genotytiping Methods. D. Vicent-Baz, A. Paredes, T. Morán, B. Massuti, N. Reguart, R.Alvarez, A. Insa, O. Juan-Vidal, A. Artal, E. Esteban, R. García Campelo, A. L. Ortega, P. Diz, J.L. González Larriba et al. Clin. Transl. Oncol. (en prensa)
18. Delphi Consensous on the Follow-up of Cancer Patients with Breakthrough Pain Under Opioid Treatment. J.L. González Larriba, D. Cayuela, O. Fernandez, S. Garcerá, R.Molina, JJ Reina, V. Guillem, C. Camps, M. Feyjoo. SN Comprehensive Clinical Medicine 2019; 1:891-899. https://doi.org/10.1007/s42399-019-00125-x.
19. Lung Cancer in Spain: information from the Thoracic Tumors Regisitry (TTR study). M. Provencio, E. Carcereny, D. Rodríguez-Abreu, R. López-Castro, M. Guirado, C. Camps, J. Bosch-Barrera, R. García Campleo, A. Ortega Granados, J.L. González Larriba et al. Transl.Lung Cancer Res. 2019; 8:461-475; doi: 10.21037/tlcr.2019.08.05
20. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangemets in Patients with Non-Small Cell Lung Carcinoma: The Rosing Study. E. Conde, S. Hernandez, R. Martínez, B. Angulo, J. de Castro, A. Collazo-Lorduy, B. Jiménez, A. Muriel, J.L. Matye, T. Morán, I. Aranda, B. Massuti, F. Rojo, M. Dominé, I. Sansano, F. García, E. FElip, N. Mancheño, O. Juan, J. Sanz, J.L. González Larriba et al. J.Thor.Oncology. 2019; 14:2120-2132. ISSN: 1556-0864
21. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cáncer: The BRCA1-RAP80 Expression Customization (BREC) studies. Referenciado como participante en el estudio. Annals of Oncology 25; 2147-2155, 2014.